Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-qs9v7 Total loading time: 0 Render date: 2024-07-12T08:39:49.192Z Has data issue: false hasContentIssue false

Section 14 - Autotransplants for Solid Neoplasms

Published online by Cambridge University Press:  24 May 2017

Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 485 - 500
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Einhorn, LH. Treatment of testicular cancer: a new and improved model. JClin Oncol 8:1777–1781, 1990CrossRefGoogle ScholarPubMed
Nichols, CR, Tricot, G, Williams, SD et al. Dose-intensive chemotherapy in refractory germ cell cancer. A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932–939, 1989CrossRefGoogle ScholarPubMed
Nichols, CR, Anderson, J, Lazarus, HM, et al. High dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group Protocol. J Clin Oncol 10:558–563, 1992CrossRefGoogle ScholarPubMed
Lorch, A, Kollmannsberger, C, Hartmann, JT, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 25:2778–84, 2007CrossRefGoogle ScholarPubMed
Einhorn, LH, Williams, SD, Chamness, A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340–8, 2007CrossRefGoogle ScholarPubMed
Lorch, A, Beyer, J, Bascoul-Mollevi, C, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28:4906–11, 2010Google ScholarPubMed
Pico, JL, Rosti, G, Kramar, A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16:1152–9, 2005CrossRefGoogle ScholarPubMed
Lorch, A, Kleinhans, A, Kramar, A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol 30:800–5, 2012CrossRefGoogle ScholarPubMed
Lorch, A, Bascoul-Mollevi, C, Kramar, A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 29:2178–84, 2011CrossRefGoogle ScholarPubMed
Albers, P, Ganz, A, Hannig, E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164:381–4, 2000CrossRefGoogle ScholarPubMed
Coogan, CL, Foster, RS, Rowland, RG, et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 50:957–62, 1997CrossRefGoogle ScholarPubMed
Beck, SD, Foster, RS, Bihrle, R, et al. Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. Urol Oncol 23:423–30, 2005CrossRefGoogle ScholarPubMed
Olofsson, SE, Tandstad, T, Jerkeman, M, et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group J Clin Oncol 29:2032–9, 2011CrossRefGoogle ScholarPubMed
Adra, N, Albany, C, Sonnenburg, D, Tong, Y, Hanna, NH, Einhorn, LH. A retrospective analysis of patients with poor-risk germ cell tumor (PRGCT) treated at Indiana University from 2000 to 2010. J Clin Oncol 31:Suppl; abstr 4557, 2013CrossRefGoogle Scholar
Chevreau, C, Droz, JP, Pico, JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non- seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 23:213–7, 1993Google ScholarPubMed
Droz, JP, Kramar, A, Biron, P et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-Volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 51:739–46, 2007CrossRefGoogle ScholarPubMed
Motzer, RJ, Mazumdar, M, Gulati, SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828–35, 1993CrossRefGoogle ScholarPubMed
Bokemeyer, C, Kollmannsberger, C, Meisner, C et al. First-line high-dose chemotherapy compared to standard- dose PEB/VIP chemotherapy in patients with advanced germ cell tumors. A multivariate and matched pair analysis. J Clin Oncol; 17:3450–6, 1999CrossRefGoogle ScholarPubMed
Motzer, RJ, Nichols, CJ, Margolin, KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247–56, 2007CrossRefGoogle ScholarPubMed

References

Pizzo, PA, Poplack, DG. Principles and Practice of Pediatric Oncology, 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2002.Google Scholar
Matthay, KK, Villablanca, JG, Seeger, RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341; 1165–1173.CrossRefGoogle ScholarPubMed
Matthay, KK, Reynolds, CP, Seeger, RC et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group study. J Clin Oncol 2009; 27: 1007–1013.CrossRefGoogle ScholarPubMed
Yu, AL, Gilman, AL, Ozkaynak, O et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324–1334.CrossRefGoogle ScholarPubMed
Yalcin, B, Kremer, LC, Caron, HN, van Dalen, EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev 2013; 8: 1–41.Google Scholar
Berthold, F, Boos, J, Burcahc, S et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma. A randomized controlled trial. Lancet Oncol 2005; 6: 649–658.CrossRefGoogle Scholar
Pritchard, J, Cotterill, SJ, Germond, SM et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomized trial (ENSG-1) by the European Neuroblastoma Study Group. Cancer 2005; 44: 348–357.Google ScholarPubMed
Cheung, NV, Heller, G. Chemotherapy dose intensity correlates strongly with the response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050–1058.CrossRefGoogle ScholarPubMed
Kletzel, M, Katzenstein, HM, Hauk, PR et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem cell rescue: results of the Chicago pilot II study. J Clin Oncol 2002: 20: 2284–2292.CrossRefGoogle ScholarPubMed
Seif, AE, Naranjo, A, Baker, DL et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013; 48: 947–952.CrossRefGoogle Scholar
Grupp, SA, Dvorak, CC, Nieder, ML et al. COG Stem Cell Transplant Scientific Committee. Children’s Oncology Group’s 2013 blueprint for research: Stem cell transplantation. Pediatr Blood Cancer. 2013; 60: 1044–1047.CrossRefGoogle ScholarPubMed
Gadner, H, Emminger, W, Ladenstein, R, Peters, C. High-dose melphalan, etoposide, and carboplatin (MEC) +/- fractionated total body irradiation for treatment of advanced solid tumors. Pediatr Hematol Oncol. 1992; 9: v-viii.CrossRefGoogle ScholarPubMed
Flandin, I, Hartmann, O, Michon, J et al. Impact of TBI on late effects in children treated by megatherapy for stage IV neuroblastoma. A study for the French Society of Pediatric Oncology. In J Radiat Oncol Biol Phys 2006: 64; 1424–1431.CrossRefGoogle ScholarPubMed
Hobbie, WL, Moshang, T, Carlson, CA et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 2008; 51: 679–683.CrossRefGoogle ScholarPubMed
Kushner, BH, Cheung, NKV, Kramer, K, Dunkel, IJ, Calleja, E, Boulad, F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 2001; 28: 551–556.CrossRefGoogle ScholarPubMed
DE Ioris, MA, Contoli, B, Jenkner, A et al. Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma. Anticancer Res 2012; 32: 5427–5434.Google ScholarPubMed
Molina, B, Alonso, L, Gonzalez-Vicent, M et al. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastama patients. Pediatr Hematol Oncol 2011; 28: 115–123.CrossRefGoogle Scholar
Boland, I, Vassal, G, J Morizet, J, et al. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 1999; 79: 787–792.CrossRefGoogle ScholarPubMed
Ladenstein, R, Potschger, U, Hartman, O et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008; 41(Suppl 2): S118–127.CrossRefGoogle ScholarPubMed
Hamidieh, AA, Beiki, D, Paragomi, P, et al. The potential role of pretransplant MIBG diagnosic scintigraphy in targeted administration of I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: A pilot study. Pediatr Transplant 2014; 18: 510–517.CrossRefGoogle Scholar
Atas, E, Kesik, V, Kismet, E, Kosseoglu, V. 131I-Metaiodobenzylguanidine conditioning regimen in children with neuroblastoma undergoing stem cell transplantation. Pediatr Transplant 2013; 17: 407–408.CrossRefGoogle ScholarPubMed
French, S, Dubois, SG, Horn, B et al. I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013; 60: 879–884.CrossRefGoogle Scholar
Matthay, KK, DeSantes, K, Hasagawa, B et al. Phase 1 dose escalation of I131-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229–236.CrossRefGoogle Scholar
Matthay, KK, Tan, JC, Villablanca, JG et al. Phase 1 dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem cell transplantation in refractory neuroblastoma: a New Approaches to Neuroblastoma therapy Consortium Study. J Clin Oncol 2006; 24: 500–506.CrossRefGoogle ScholarPubMed
Rill, DR, Santana, VM, Roberts, WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380–383.CrossRefGoogle ScholarPubMed
Donovan, J, Temel, J, Zuckerman, A et al. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol 2000; 35: 677–682.3.0.CO;2-H>CrossRefGoogle ScholarPubMed
Marabelle, A, Merlin, E, Halle, P et al. CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma. Pediatr Blood Cancer 2011; 56: 134–142.CrossRefGoogle ScholarPubMed
Handgretinger, R, Leung, W, Ihm, K et al. Tumour cell contamination of autologous stem cell grafts in high-risk neuroblastoma: the good news? Br J Cancer 2003; 88: 1874–1877.CrossRefGoogle ScholarPubMed
Kreissman, SG, Seeger, RC, Matthay, KM et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomized phase 3 trial. Lancet Oncol 2013; 14: 999–1008.CrossRefGoogle Scholar
Park, JE, Scott, JR, Stewart, JF et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. J Clin Oncol 2011; 29: 4351–4357.CrossRefGoogle ScholarPubMed
Beiske, K, Burchill, SA, Cheung, IY et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009; 100: 1627–1637.CrossRefGoogle ScholarPubMed
Cheung, IY, Feng, Y, Gerald, W, Cheung, NV. Exploiting gene expression profiling to novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 2008; 14: 7020–7027.CrossRefGoogle ScholarPubMed
Ladenstein, R, Lasset, C, Hartmann, O et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: Report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 37–46.Google Scholar
Hale, GA, Arora, M, Ahn, KW et al. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant 2013; 48: 1056–1064.CrossRefGoogle ScholarPubMed
Jubert, C, Wall, DA, Grimley, M et al. Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial. Bone Marrow Transplant 2011; 46: 232–237.CrossRefGoogle ScholarPubMed
Geyer, MB, Jacobson, JS, Freedman, J et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning (MAC) vs. reduced toxicity conditioning (RTC) and umbilical cord blood transplantation (UCBT) in paediatric recipients. Br J Haematol 2011; 155: 218–234.CrossRefGoogle Scholar
Pession, A, Masetti, R, Di Leo, C et al. HLA-mismatched hematopoietic stem cell transplantation for pediatric solid tumors. Pediatr Rep 2011; 3(Suppl 2): e12.CrossRefGoogle ScholarPubMed
Sung, KW, Park, JE, Cheuh, HW et al. Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr Blood Cancer 2011; 57: 680–685.CrossRefGoogle ScholarPubMed
Paillard, C, Rochette, E, Lutz, P et al. Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Société Française des Cancers de l’Enfant and the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Bone Marrow Transplant 2013; 48: 1401–1408.CrossRefGoogle ScholarPubMed
Sato, Y, Kurosawa, H, Fukushima, K et al. I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma. Ital J Pediatr 2012; 15: 1–3.Google Scholar
Toporski, J, Garkavij, M, Tennvall, J et al. High dose iodine-131-metaiodobenzylguadine with haploidentical stem cell transplantation and posttransplant immunotherapt in children with relapsed/refractory neuroblastoma. Biol Blood Marrow Transplant 2009; 12: 1077–1085.CrossRefGoogle Scholar
Takahashi, H, Manabe, A, Aoyama, C et al. Iodine 131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma. Pediatr Blood Cancer 2008; 50: 676–678.CrossRefGoogle Scholar
Inoue, M, Nakano, T, Yoneda, A et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 2003; 32: 103–106.CrossRefGoogle Scholar
Ash, S, Stein, J, Ashenasv, N, Yaniv, I. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation. Br J Cancer 2010; 103: 1597–1605.CrossRefGoogle ScholarPubMed
Ash, S, Gigi, V, Askenasy, N et al. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD. Cancer Immunol Immunother 2009; 58 : 2073–2084.CrossRefGoogle ScholarPubMed
Venstrom, JM, Zheng, J, Noor, N et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009; 15: 7330–7334.CrossRefGoogle ScholarPubMed
Barker, E, Mueller, BM, Handgretinger, R, Herter, M, Yu, AL, Reisfeld, A. Effect of a chimeric anti-ganglioside GDS2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991; 51: 144–149.Google Scholar
Hank, JA, Robinson, RR, Surfus, J et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990; 50: 5234–5239.Google ScholarPubMed
Gilman, AL, Ozkaynak, MF, Matthay, KK et al. Phase 1 study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children’s Oncology Group. J Clin Oncol 2009; 27: 85–91.CrossRefGoogle ScholarPubMed
Ozkaynak, MF, Sondel, PM, Krailo, MD et al. Phase 1 study of chimeric human/murine anti-ganglioside G9D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group Study. J Clin Oncol 2000; 18: 4077–4085.CrossRefGoogle Scholar
Delgado, DC, Hank, JA, Kolesar, J et al. Genotypes of NK cell KIR receptros, their ligands, and Fc gamma recdiptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010; 70: 9554–9561.CrossRefGoogle Scholar
Bottino, C, Dondero, A, Bellora, F et al. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol 2014; 5: 1–11.CrossRefGoogle ScholarPubMed
Leung, W, Handgretinger, R, Iyengar, R, Turner, V, M S Holladay, MS, Hale, GA Inhibitory KIR-HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007; 97: 539–542.CrossRefGoogle ScholarPubMed
Venstrom, JM, Zheng, J, Noor, N et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009; 15: 7330–7334.CrossRefGoogle ScholarPubMed
Jing, W, Gershan, JA, Johnson, BD. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of anti-tumor immune memory. Blood 2009; 113: 4449–4457.CrossRefGoogle Scholar
Cui, Y, Zhang, H, Meadors, J, Poon, R, Guimond, M, Mackall, CL. Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009; 114: 3831–3840.CrossRefGoogle ScholarPubMed
Miller, JS, Weisdorf, DJ, Burns, LJ et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007; 110: 2761–2763.CrossRefGoogle ScholarPubMed
Baba, J, Watanabe, S, Saida, Y et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 2012; 120: 2417–2427.CrossRefGoogle ScholarPubMed
Louis, CU, Straathof, K, Bollard, CM et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009; 113: 2442–2450.CrossRefGoogle ScholarPubMed
Grupp, SA, Prak, EL, Boyer, J et al. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res. 2012; 18: 6732–6741.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×